Mar 12, 2020

Lung Cancer Update, Issue 1, 2020: Our interview with Dr Ko highlights the following topics as well as cases from his practice:

• Case: A man in his mid-50s with metastatic non-small cell lung cancer (NSCLC) and an ALK rearrangement receives brigatinib as first-line therapy on the ALTA-1L trial (00:00)
• Results from the Phase III ALTA-1L and ALEX studies evaluating brigatinib or alectinib versus crizotinib for patients with advanced NSCLC and an ALK rearrangement (02:33)
• Side effects, dosing and quality of life with alectinib and brigatinib (06:51)
• Early onset pulmonary events associated with brigatinib (08:47)
• Activity of lorlatinib as second- or third-line therapy for NSCLC with an ALK rearrangement (11:39)
• Targeting the MET pathway for patients with NSCLC who experience disease progression on EGFR and ALK inhibitors (14:15)
• Treatment for patients with metastatic NSCLC and an ALK rearrangement who experience disease progression on an ALK inhibitor (17:01)
• Perspective on the potential identification of patients who might experience rapid disease progression on ALK inhibitors (19:26)
• Role of immune checkpoint inhibitors for patients with metastatic NSCLC and targetable mutations (22:51)
• PD-L1 expression as a predictive biomarker for patients with actionable alterations; approach to the use of immunotherapy (26:03)
• Treatment for patients with metastatic NSCLC and EGFR mutations who have experienced disease progression after targeted therapy (28:40)
• Case: A woman in her early 50s with metastatic NSCLC and an EGFR exon 20 insertion experiences disease progression after treatment with TAK-788 and whole-brain radiation therapy (32:22)
• Perspective on dementia associated with whole-brain radiation therapy (35:10)
• Guidelines from the Response Assessment in Neuro-Oncology Brain Metastases working group: Clinical trial design for systemic agents for brain metastases (39:27)
• Hippocampus sparing during radiation therapy for brain metastases (41:08)
• Targeting EGFR exon 20 insertions with TAK-788 and poziotinib (42:40)
• Incidence of NTRK alterations and treatment for patients with NTRK alterations (46:22)
• Case: A man in his mid-60s, a heavy smoker, with metastatic squamous cell lung carcinoma and MET amplification receives carboplatin/paclitaxel/pembrolizumab as first-line therapy (48:51)
• Choice of chemotherapy for patients with metastatic squamous cell lung cancer and targetable alterations (52:16)
• Efficacy of the selective MET inhibitors tepotinib and capmatinib for patients with advanced NSCLC and MET exon 14 skipping mutations (53:56)
• Prognosis and treatment for patients with NSCLC and KRAS mutations (57:37)
• Predictors of benefit with immunotherapy for patients with NSCLC (59:39)
• Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies for NSCLC (1:00:55)

CME information and select publications